CC Investors Have Opportunity to Lead The Chemours Company Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Oct. 19, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against The Chemours Company ("Chemours" or "the Company") (NYSE: CC) for violations of §§10(b) and 20(a) of the...
Covered in this story
Analyst targets on Chemours
- RBC Capital Markets: $13.4 → $14 by Oct 2027 · Sector Perform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $CC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Chemours →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.